{
    "nct_id": "NCT03409458",
    "official_title": "A Phase 1b/2a Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab",
    "inclusion_criteria": "1. Histologically or cytologically confirmed metastatic or locally advanced, squamous or non-squamous NSCLC (NSCLC). Patients must have received no more than four prior lines of therapy, including a PD-1 / PD-L1-containing therapy and a platinum containing regimen. Patients must have received no more than one taxane containing regimen and no more than one investigational agent;\n2. Must provide study-related tumor specimens;\n3. ECOG(PS) 0-1;\n4. Estimated Life Expectancy > 3 months;\n5. Adequate bone marrow (BM), renal, hepatic and metabolic function.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Concurrent cancer treatment with cytoreductive therapy, radiotherapy, cytokine therapy, cytotoxic agents, targeted small molecule therapy or any investigational anticancer small molecule drugs within 2 weeks prior to the start of study treatment (except 5 weeks from last dose of nitrosourea compound) OR treatment with monoclonal antibodies within 4 weeks prior to the start of study treatment;\n2. Known symptomatic central nervous system (CNS) metastases requiring steroids.\n3. Diagnosis of any other malignancy within 2 years prior to enrollment;\n4. Vaccination within 4 weeks of the first dose of study treatment is prohibited except for administration of inactivated vaccines;\n5. Current use of immunosuppressive medication at study entry;\n6. Active or prior autoimmune disease that might deteriorate with receiving an immunostimulatory agent;\n7. Acute or chronic infections requiring systemic therapy;\n8. Known history of autoimmune colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis;\n9. Known intolerance to checkpoint inhibitor therapy, defined by the occurrence of an AE leading to drug discontinuation;\n10. Participation in other studies involving investigational drug(s) within 28 days prior to study entry and/or during study participation.",
    "miscellaneous_criteria": "Key"
}